These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 18505772

  • 1. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [Abstract] [Full Text] [Related]

  • 2. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group.
    Neurology; 2005 Jul 12; 65(1):33-9. PubMed ID: 15888603
    [Abstract] [Full Text] [Related]

  • 3. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 12; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 4. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 5. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS, Koch-Henriksen N, Bendtzen K.
    Mult Scler; 2007 Jun 12; 13(5):616-21. PubMed ID: 17548440
    [Abstract] [Full Text] [Related]

  • 6. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G.
    Clin Chim Acta; 2008 May 12; 391(1-2):98-101. PubMed ID: 18249193
    [Abstract] [Full Text] [Related]

  • 7. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D, Sellebjerg F, Sorensen PS.
    Neurology; 2009 Aug 04; 73(5):372-7. PubMed ID: 19652141
    [Abstract] [Full Text] [Related]

  • 8. Neutralizing antibodies to interferon.
    Noronha A.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [Abstract] [Full Text] [Related]

  • 9. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [Abstract] [Full Text] [Related]

  • 10. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
    Farrell R, Kapoor R, Leary S, Rudge P, Thompson A, Miller D, Giovannoni G.
    Mult Scler; 2008 Mar 25; 14(2):212-8. PubMed ID: 17986510
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
    Clin Ther; 2007 Jun 25; 29(6):1128-45. PubMed ID: 17692727
    [Abstract] [Full Text] [Related]

  • 12. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS, Rice GP, Alsop JC, PRISMS Study Group.
    Neurology; 2005 Jul 12; 65(1):48-55. PubMed ID: 16009884
    [Abstract] [Full Text] [Related]

  • 13. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
    Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C, BEYOND Study Group.
    Mult Scler; 2012 Feb 12; 18(2):181-95. PubMed ID: 21952094
    [Abstract] [Full Text] [Related]

  • 14. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
    Bellomi F, Bramanti P, Trojano M, Scagnolari C, Muto A, Sessa E, La Volpe V, Russo P, Antonelli G.
    J Immunoassay Immunochem; 2009 Feb 12; 30(1):40-50. PubMed ID: 19117201
    [Abstract] [Full Text] [Related]

  • 15. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J.
    Mult Scler; 2009 Feb 12; 15(2):212-8. PubMed ID: 18805837
    [Abstract] [Full Text] [Related]

  • 16. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C, BENEFIT Study Group.
    Neurology; 2011 Aug 30; 77(9):835-43. PubMed ID: 21849647
    [Abstract] [Full Text] [Related]

  • 17. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J.
    Arch Neurol; 2010 Apr 30; 67(4):402-7. PubMed ID: 20142519
    [Abstract] [Full Text] [Related]

  • 18. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
    Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M.
    Mult Scler; 2007 Aug 30; 13(7):895-9. PubMed ID: 17468449
    [Abstract] [Full Text] [Related]

  • 19. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A, Rudzki D, Hölzl M, Ehling R, Gneiss C, Künz B, Berger T, Reindl M, Deisenhammer F.
    Mult Scler; 2009 Aug 30; 15(8):977-83. PubMed ID: 19465447
    [Abstract] [Full Text] [Related]

  • 20. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P, Calabrese M, Biasi G, Gallo P.
    J Neurol; 2004 Mar 30; 251(3):305-9. PubMed ID: 15015010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.